Table 5 Immunogenicity—total incidence of ADAs
Antibody positive by week 22 with a negative or no result at baseline | Antibody positive post week 22 with a negative or no result at week 22 | ||||
|---|---|---|---|---|---|
ABP 710 | RP | ABP 710/ABP 710 | RP/RP | RP/ABP 710 | |
Number of patients | 261 | 264 | 96 | 45 | 45 |
Binding antibody, n (%) | 149 (57.1) | 160 (60.6) | 29 (30.2) | 19 (42.2) | 18 (40.0) |
Neutralizing antibody, n (%) | 47 (18.0) | 55 (20.8) | 3 (3.1) | 1 (2.2) | 2 (4.4) |